27th Mar 2018 14:48
The biotechnology investment company recorded a pretax loss of
The company's net asset value per share at period end was
"Whilst our current investments continue to make encouraging progress, the board is also evaluating a number of further investments within our investing policy which we believe have considerable future potential," Chairman Jim Mellon said.
Shares in the company were untraded at
Related Shares:
PEBI.L